medigraphic.com
ISSN 2007-1523 (Electronic)
Revista Mexicana de Trastornos Alimentarios

2022, Number 1

<< Back Next >>

Revista Mexicana de Trastornos Alimentarios 2022; 12 (1)

The effect of probiotics in the treatment and prevention of metabolic syndrome: a systematic review

Rivero-García PC, Monroy-Torres R

Language: Spanish
References: 58
Page: 71-87
PDF size: 993.09 Kb.


ABSTRACT

There is consistent clinical evidence, but not yet conclusive, that the consumption of foods or supplements based on probiotics modifies the microbiota and the microenvironment, with beneficial effects that are manifested in the clinical, anthropometric, and biochemical components of metabolic syndrome (MS) in the adult population. The objective of this systematic review was to analyze the effects of probiotic supplementation on the prevention and treatment of MS and its components in the adult population. A systematic review was carried out in the databases: Pubmed-Medline, Scopus, Web of Science, LILACS, Cochrane, SIGN, NICE and Scielo, with articles in Spanish and English from 2010 to 2020, with controlled intervention designs where have compared probiotic supplementation (regardless of dose, strains, route of administration, or duration of use). Sixteen articles were selected (10 randomized clinical trials (RCTs), which included 610 participants). The meta-analysis carried out indicated that no statistically significant differences were found on insulin resistance (HOMA-IR), obesity (body mass index -BMI-), atherogenic dyslipidemia or on blood pressure. These findings conclude the lack of evidence found to recommend the consumption of probiotics as a strategy to reduce the prevalence of MS. The methodological limitations found among the reviewed studies imply the need for future lines of research on its relevance as a potential nutritional therapy and for the moment it is recommended to integrate variables such as nutritional treatment or diet control.


REFERENCES

  1. Aburto, J. M., Riffe, T., & Canudas-Romo, V. (2018).Trends in avoidable mortality over the life course inMexico, 1990-2015: A cross-sectional demographicanalysis. BMJ Open, 8(7), 1–11. https://doi.org/10.1136/bmjopen-2018-022350

  2. Aguilar-Salinas, C. A., Rojas, R., Gómez-Pérez, F. J., Franco,A., Olaiz, G., Rull, J. A., & Sepúlveda, J. (2004). Elsíndrome metabólico: Un concepto en evolución. GacetaMedica de Mexico, 140(Suppl. 2), 41–48.

  3. Aguilar-Salinas, C. A., & Viveros-Ruiz, T. (2019). Recentadvances in managing/understanding themetabolic syndrome. F1000Research, 8, 370. https://doi.org/10.12688/f1000research.17122.1

  4. Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet,P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James,W. P. T., Loria, C. M., Smith, S. C., InternationalDiabetes Federation Task Force on Epidemiology andPrevention, Hational Heart, Lung, and B. I., AmericanHeart Association, World Heart Federation, InternationalAtherosclerosis Society, & International Association forthe Study of Obesity. (2009). Harmonizing the metabolicsyndrome: A joint interim statement of the InternationalDiabetes Federation Task Force on Epidemiology andPrevention; National Heart, Lung, and Blood Institute;American Heart Association; World Heart Federation;International. Circulation, 120(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644

  5. Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006). Metabolicsyndrome—A new world-wide definition. AConsensus Statement from the International DiabetesFederation. Diabetic Medicine : A Journal of theBritish Diabetic Association, 23(5), 469–480. https://doi.org/10.1111/j.1464-5491.2006.01858.x

  6. American Diabetes Association. (2020). 6. Glycemic Targets:Standards of Medical Care in Diabetes—2020.Diabetes Care, 43(Supplement 1), S66–S76. https://doi.org/10.2337/dc20-S006

  7. Andreadis, E. A., Tsourous, G. I., Tzavara, C. K., Georgiopoulos,D. X., Katsanou, P. M., Marakomichelakis,G. E., & Diamantopoulos, E. J. (2007). Metabolic syndromeand incident cardiovascular morbidity andmortality in a Mediterranean hypertensive population.American Journal of Hypertension, 20(5), 558–564. https://doi.org/10.1016/j.amjhyper.2006.12.001

  8. Aspry, K. E., Van Horn, L., Carson, J. A. S., Wylie-Rosett,J., Kushner, R. F., Lichtenstein, A. H., Devries, S., Freeman,A. M., Crawford, A., & Kris-Etherton, P. (2018).Medical Nutrition Education, Training, and Competenciesto Advance Guideline-Based Diet Counselingby Physicians: A Science Advisory From the AmericanHeart Association. Circulation, 137(23), e821–e841. https://doi.org/10.1161/CIR.0000000000000563

  9. Barnard, N. D., Willet, W. C., & Ding, E. L. (2017). Themisuse of meta-analysis in nutrition research. JAMA- Journal of the American Medical Association, 318(15), 1435–1436. https://doi.org/10.1001/jama.2017.12083

  10. Beck-Nielsen, H. (1999). General characteristics of the insulinresistance syndrome: Prevalence and heritability.European Group for the study of Insulin Resistance(EGIR). Drugs, 58 Suppl 1, 7–10; discussion 75-82. https://doi.org/10.2165/00003495-199958001-00003

  11. Cuschieri, S. (2019). The STROBE guidelines. Saudi Journalof Anaesthesia, 13(Suppl 1), S31–S34. https://doi.org/10.4103/sja.SJA_543_18

  12. Dalle Grave, R., Calugi, S., Centis, E., Marzocchi, R., ElGhoch, M., & Marchesini, G. (2010). Lifestyle modificationin the management of the metabolic syndrome:Achievements and challenges. Diabetes, Metabolic Syndromeand Obesity : Targets and Therapy, 3, 373–385. https://doi.org/10.2147/DMSOTT.S13860

  13. Davis, T., & Edelman, S. V. (2004). Insulin therapy in type 2diabetes. Medical Clinics of North America, 88(4), 865–895.https://doi.org/10.1016/j.mcna.2004.04.005

  14. Dong, Y., Xu, M., Chen, L., & Bhochhibhoya, A. (2019).Probiotic Foods and Supplements Interventions forMetabolic Syndromes: A Systematic Review andMeta-Analysis of Recent Clinical Trials. Annals ofNutrition and Metabolism, 74(3), 224–241. https://doi.org/10.1159/000499028

  15. Durán-Varela, B. R., Rivera-Chavira, B., & Franco-Gallegos,E. (2001). Pharmacological therapy compliance indiabetes. Salud Publica de Mexico, 43(3), 233–236.

  16. Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997).Bias in meta-analysis detected by a simple, graphicaltest. British Medical Journal, 315(7109), 629–634. https://doi.org/10.1136/bmj.316.7129.469

  17. Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia,M., & Colecchia, A. (2014). Gut microbiota andmetabolic syndrome. World Journal of Gastroenterology,20(43), 16079–16094. https://doi.org/10.3748/wjg.v20.i43.16079

  18. Figueroa-Lara, A., Gonzalez-Block, M. A., & Alarcon-Irigoyen,J. (2016). Medical Expenditure for Chronic Diseasesin Mexico: The Case of Selected Diagnoses Treated bythe Largest Care Providers. PloS One, 11(1), e0145177.https://doi.org/10.1371/journal.pone.0145177

  19. Ford, E. S. (2004). The metabolic syndrome and mortalityfrom cardiovascular disease and all-causes: Findingsfrom the National Health and Nutrition ExaminationSurvey II Mortality Study. Atherosclerosis, 173(2), 309–314.https://doi.org/10.1016/j.atherosclerosis.2003.12.022

  20. Ghosh, A. (2011). The metabolic syndrome: A definition dilemma.Cardiovascular Journal of Africa, 22(6), 295–296.

  21. Grundy, S. M. (2016). Metabolic syndrome update. Trendsin Cardiovascular Medicine, 26(4), 364–373. https://doi.org/10.1016/j.tcm.2015.10.004

  22. Higgins, J. P. T., & Thompson, S. G. (2002). Quantifyingheterogeneity in a meta-analysis. Statistics in Medicine,21(11), 1539–1558. https://doi.org/10.1002/sim.1186

  23. Hillier, T. A., Rizzo, J. H., Pedula, K. L., Cauley, J. A.,Schwartz, A. V., Ensrud, K. E., & Browner, W. S.(2005). Increased Mortality Associated With theMetabolic Syndrome in Older Women With Diabetes.Diabetes Care, 28(9), 2258–2260. https://doi.org/10.2337/diacare.28.9.2258

  24. Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005). Estimatingthe mean and variance from the median, range, and thesize of a sample. BMC Medical Research Methodology, 5,1–10. https://doi.org/10.1186/1471-2288-5-13

  25. Kassaian, N., Feizi, A., Aminorroaya, A., & Amini, M.(2019). Probiotic and synbiotic supplementation couldimprove metabolic syndrome in prediabetic adults: Arandomized controlled trial. Diabetes and Metabolic Syndrome:Clinical Research and Reviews, 13(5), 2991–2996.https://doi.org/10.1016/j.dsx.2018.07.016

  26. Kassaian, N., Feizi, A., Aminorroaya, A., Jafari, P., Ebrahimi,M. T., & Amini, M. (2018). The effects of probioticsand synbiotic supplementation on glucose and insulinmetabolism in adults with prediabetes: A double-blindrandomized clinical trial. Acta Diabetologica, 55(10), 1019–1028. https://doi.org/10.1007/s00592-018-1175-2

  27. Kassaian, N., Feizi, A., Rostami, S., Aminorroaya, A., Yaran,M., & Amini, M. (2020). The effects of 6 mo ofsupplementation with probiotics and synbiotics on gutmicrobiota in the adults with prediabetes: A doubleblind randomized clinical trial. Nutrition, 79–80, 110854.https://doi.org/10.1016/j.nut.2020.110854

  28. Kaur, J. (2014). A comprehensive review on metabolic syndrome.Cardiology Research and Practice, 2014, 943162.https://doi.org/10.1155/2014/943162

  29. Kim, S. K., Guevarra, R. B., Kim, Y. T., Kwon, J., Kim,H., Cho, J. H., Kim, H. B., & Lee, J. H. (2019). Roleof probiotics in human gut microbiome-associated diseases.Journal of Microbiology and Biotechnology, 29(9),1335–1340. https://doi.org/10.4014/jmb.1906.06064

  30. Lakka, H.-M., Laaksonen, D. E., Lakka, T. A., Niskanen,L. K., Kumpusalo, E., Tuomilehto, J., & Salonen, J. T.(2002). The metabolic syndrome and total and cardiovasculardisease mortality in middle-aged men. JAMA,288(21), 2709–2716.

  31. Lee, C. J., Sears, C. L., & Maruthur, N. (2019). Gut microbiomeand its role in obesity and insulin resistance. InAnnals of the New York Academy of Sciences (pp. 1–16). https://doi.org/10.1111/nyas.14107

  32. Liang, H., Hussey, S. E., Sanchez-Avila, A., Tantiwong, P.,& Musi, N. (2013). Effect of Lipopolysaccharide on Inflammationand Insulin Action in Human Muscle. PLoSONE, 8(5), 8–15. https://doi.org/10.1371/journal.pone.0063983

  33. Llewellyn, A., & Foey, A. (2017). Probiotic modulation ofinnate cell pathogen sensing and signaling events. InNutrients (Vol. 9, Issue 10). https://doi.org/10.3390/nu9101156

  34. Martin, C. R., & Walker, W. A. (2008). Probiotics: Role inPathophysiology and Prevention in Necrotizing Enterocolitis.Seminars in Perinatology, 32(2), 127–137. https://doi.org/10.1053/j.semperi.2008.01.006

  35. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., &PRISMA Group. (2009). Preferred reporting items forsystematic reviews and meta-analyses: The PRISMAstatement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097

  36. Monami, M., Marchionni, N., Masotti, G., & Mannucci, E.(2007). IDF and ATP-III definitions of metabolic syndromein the prediction of all-cause mortality in type 2 diabeticpatients. Diabetes, Obesity & Metabolism, 9(3), 350–353. https://doi.org/10.1111/j.1463-1326.2006.00615.x

  37. Montesi, L., Ghoch, M. El, Brodosi, L., Calugi, S., Marchesini,G., & Grave, R. D. (2016). Long-term weight lossmaintenance for obesity: A multidisciplinary approach.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy,9, 37–46. https://doi.org/10.2147/DMSO.S89836

  38. Muñoz-Martín, B., & Higgins JPT, Green S, Editores.(2012). Manual Cochrane de Revisiones Sistemáticas deIntervenciones, versión 5.1. 0. Manual Cochrane de RevisionesSistemáticas de Intervenciones, Versión 5.1.0, 7(3), 1–639.https://doi.org/10.14201/orl201673.14814

  39. National Cholesterol Education Program (NCEP) ExpertPanel on Detection, Evaluation, and T. of H. B. C. in A.(Adult T. P. I. (2002). Third Report of the National CholesterolEducation Program (NCEP) Expert Panel onDetection, Evaluation, and Treatment of High BloodCholesterol in Adults (Adult Treatment Panel III) finalreport. Circulation, 106(25), 3143–3421.

  40. OPS/OMS | Diabetes. (n.d.).

  41. Palaniappan, L., Carnethon, M. R., Wang, Y., Hanley, A. J.G., Fortmann, S. P., Haffner, S. M., Wagenknecht, L., &Insulin Resistance Atherosclerosis Study. (2004). Predictorsof the incident metabolic syndrome in adults: TheInsulin Resistance Atherosclerosis Study. Diabetes Care,27(3), 788–793.

  42. Pascale, A., Marchesi, N., Marelli, C., Coppola, A., Luzi,L., Govoni, S., Giustina, A., & Gazzaruso, C. (2018).Microbiota and metabolic diseases. Endocrine, 61(3),357–371. https://doi.org/10.1007/s12020-018-1605-5

  43. Pérez, E. A., González, M. P., Martínez-Espinosa, R. M.,Vila, M. D. M., & García-Galbis, M. R. (2019). Practicalguidance for interventions in adults with metabolicsyndrome: Diet and exercise vs. Changes in body composition.International Journal of Environmental Researchand Public Health, 16(18). https://doi.org/10.3390/ijerph16183481

  44. Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018).The pharmacological management of metabolic syndrome.Expert Review of Clinical Pharmacology, 11(4),397–410. https://doi.org/10.1080/17512433.2018.1429910

  45. Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano,G. A. D., Gasbarrini, A., & Mele, M. C. (2019).What is the healthy gut microbiota composition? Achanging ecosystem across age, environment, diet, anddiseases. Microorganisms, 7(1). https://doi.org/10.3390/microorganisms7010014

  46. Ritchie, S. A., & Connell, J. M. C. (2007). The link betweenabdominal obesity, metabolic syndrome andcardiovascular disease. Nutrition, Metabolism, and CardiovascularDiseases : NMCD, 17(4), 319–326. https://doi.org/10.1016/j.numecd.2006.07.005

  47. Rondanelli, M., Faliva, M. A., Perna, S., Giacosa, A., Peroni,G., & Castellazzi, A. M. (2017). Using probiotics inclinical practice: Where are we now? A review of existingmeta-analyses. Gut Microbes, 8(6), 521–543. https://doi.org/10.1080/19490976.2017.1345414

  48. Sáez-Lara, M. J., Robles-Sanchez, C., Ruiz-Ojeda, F. J.,Plaza-Diaz, J., & Gil, A. (2016). Effects of probioticsand synbiotics on obesity, insulin resistance syndrome,type 2 diabetes and non-alcoholic fatty liver disease: Areview of human clinical trials. International Journal ofMolecular Sciences, 17(6), 1–15. https://doi.org/10.3390/ijms17060928

  49. Sanders, M. E. (2008). Probiotics: Definition, Sources, Selection,and Uses. Clinical Infectious Diseases, 46(s2), S58–S61.https://doi.org/10.1086/523341

  50. Soto-Estrada, G., Moreno-Altamirano, L., & Pahua-Díaz,D. (2013). Panorama epidemiológico de México, principalescausas de morbilidad y mortalidad. Revista de LaFacultad de Medicina (México), 56(3), 44–46.

  51. Stadlbauer, V., Leber, B., Lemesch, S., Trajanoski, S., Bashir,M., Horvath, A., Tawdrous, M., Stojakovic, T., Fauler,G., Fickert, P., Högenauer, C., Klymiuk, I., Stiegler, P.,Lamprecht, M., Pieber, T. R., Tripolt, N. J., & Sourij,H. (2015). Lactobacillus casei Shirota supplementationdoes not restore gut microbiota composition and gut barrierin metabolic syndrome: A randomized pilot study.PLoS ONE, 10(10), 1–14. https://doi.org/10.1371/journal.pone.0141399

  52. Strazzullo, P., Barbato, A., Siani, A., Cappuccio, F. P., Versiero,M., Schiattarella, P., Russo, O., Avallone, S., dellaValle, E., & Farinaro, E. (2008). Diagnostic criteria formetabolic syndrome: A comparative analysis in anunselected sample of adult male population. Metabolism:Clinical and Experimental, 57(3), 355–361. https://doi.org/10.1016/j.metabol.2007.10.010

  53. Szulińska, M., Łoniewski, I., Skrypnik, K., Sobieska, M.,Korybalska, K., Suliburska, J., & Bogdański, P. (2018a).Multispecies probiotic supplementation favorably affectsvascular function and reduces arterial stiffness in obesepostmenopausal women—A 12-week placebo-controlledand randomized clinical study. Nutrients, 10(11).https://doi.org/10.3390/nu10111672

  54. Szulińska, M., Łoniewski, I., van Hemert, S., Sobieska, M.,& Bogdański, P. (2018b). Dose-dependent effects ofmultispecies probiotic supplementation on the lipopolysaccharide(LPS) level and cardiometabolic profile inobese postmenopausal women: A 12-week randomizedclinical trial. Nutrients, 10(6). https://doi.org/10.3390/nu10060773

  55. Tenorio-Jiménez, C., Martínez-Ramírez, M. J., Gil, Á., &Gómez-Llorente, C. (2020). Effects of probiotics on metabolicsyndrome: A systematic review of randomizedclinical trials. Nutrients, 12(1). https://doi.org/10.3390/nu12010124

  56. Tripolt, N. J., Leber, B., Blattl, D., Eder, M., Wonisch, W.,Scharnagl, H., Stojakovic, T., Obermayer-Pietsch, B.,Wascher, T. C., Pieber, T. R., Stadlbauer, V., & Sourij, H.(2013). Short communication: Effect of supplementationwith Lactobacillus casei Shirota on insulin sensitivity,β-cell function, and markers of endothelial function andinflammation in subjects with metabolic syndrome-A pilotstudy. Journal of Dairy Science, 96(1), 89–95. https://doi.org/10.3168/jds.2012-5863

  57. Tripolt, N. J., Leber, B., Triebl, A., Köfeler, H., Stadlbauer,V., & Sourij, H. (2015). Effect of Lactobacillus casei Shirotasupplementation on trimethylamine-N-oxide levelsin patients with metabolic syndrome: An open-label,randomized study. Atherosclerosis, 242(1), 141–144. https://doi.org/10.1016/j.atherosclerosis.2015.05.005

  58. Zafar, U., Khaliq, S., Usman, H., Manzoor, S., & Lone, K.(2018). Metabolic syndrome: An update on diagnosticcriteria, pathogenesis, and genetic links. Hormones, 17,299–313.




2020     |     www.medigraphic.com